enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.
企業コードNVNO
会社名enVVeno Medical Corp
上場日May 31, 2018
最高経営責任者「CEO」Mr. Robert A. Berman
従業員数37
証券種類Ordinary Share
決算期末May 31
本社所在地70 Doppler
都市IRVINE
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号92618
電話番号19492612900
ウェブサイトhttps://envveno.com/
企業コードNVNO
上場日May 31, 2018
最高経営責任者「CEO」Mr. Robert A. Berman
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし